Warrior Spirit: An Interview with Victoria Gray, Sickle Cell Pioneer
By Victoria Gray, Uduak Thomas, and Kevin Davies,
The CRISPR Journal
| 02. 14. 2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell warrior and a true pioneer in the world of CRISPR and cell therapy. That process began 4.5 years ago. Today, she is healthy, enjoying a pain-free life with her family and friends—as are dozens of other sickle cell patients who participated in the trial. In December 2023, the U.S. Food and Drug Administration (FDA) approved Casgevy, setting a list price of $2.2 million for the one-time therapy. In January 2024, Executive Editor Kevin Davies and GEN Senior Editor Uduak Thomas interviewed Gray for “The State of Cell and Gene Therapy,” a GEN virtual summit that was broadcast on January 24, 2024.
(This interview has been lightly edited for length and clarity.)
Victoria, how are you feeling today?
Gray: I'm still doing good—way better than I expected in the beginning. So life is good for me right now.
What can you...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...